Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

California Trim Clinic vs Medro

California Trim Clinic
Graded #471

Lower grade

vs+10.399999999999999
Medro
Graded #255

Higher grade

The verdict

Medro takes it — 63.6/100 to 53.2/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +5
45
50
Dose & formulationMedro +37
40
77
Clinical oversightCalifornia Trim Clinic +5
76
71
Labs & monitoringCalifornia Trim Clinic +11
63
52
FulfillmentMedro +28
64
92
Contract termsMedro +13
20
33
California Trim Clinic · left barMedro · right bar

The numbers

MetricCalifornia Trim ClinicMedro
WeighScore53.2/10063.6/100
GradeCC
Scorecard rank#471#255
SemaglutideNot disclosed$199/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
California Trim Clinic

Graded #471 · C

Strengths

  • Women's microdosing program specifically designed for perimenopause/menopause weight management
  • 100% virtual nationwide telehealth; medications shipped discreetly to patients' homes
  • 503A state-licensed compounding pharmacies with patient-specific prescription preparation
  • $199 initial plan covers doctor consultation, telehealth setup, and full onboarding
  • Ongoing 3-month treatment plans include compounded medication and licensed provider check-ins

Where it loses points

  • Ongoing medication pricing not publicly disclosed — revealed only after $199 intake and provider approval
  • No LegitScript certification or any other third-party accreditation visible on the site
  • No physician names or clinical leadership disclosed publicly
  • States served listed as 'nationwide' for telehealth but no state-by-state list published
  • Microdose framing uses sub-clinical doses — potentially lower weight-loss efficacy than standard GLP-1 protocols
Medro

Graded #255 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard